argenx NV ADR(ARGX)— 同类公司组
数据截至2026-09-23 — 评分每个交易日晚间重新计算。分组标准=首先为共同的Closelook指数成分,其次为行业。Closelook研究日记,不构成投资建议。
argenx NV ADR的Closelook综合评分为64/100,在同类公司组内排名第2位(共7家)——组内评分最高的是BB Biotech AG(74/100)。
| 名称 | 综合 | 动量 | 质量 | 估值 | 信号 | 距52周高点 |
|---|---|---|---|---|---|---|
| ARGX argenx NV ADR | 64 | 74 | 74 | 27 | ok | 11.8% |
| BION.SW BB Biotech AG | 74 | 69 | 96 | 80 | info | 9.6% |
| ARGX.BR Argen-X | 64 | 74 | 75 | 28 | ok | 9.6% |
| ONC BeiGene, Ltd. | 64 | 81 | 64 | 32 | ok | 5.2% |
| CAI Caris Life Sciences, Inc. Common Stock | 60 | 82 | 61 | 31 | ok | 6% |
| REGN Regeneron Pharmaceuticals Inc | 60 | 68 | 71 | 50 | bull | 6.5% |
| UCB.BR UCB SA | 60 | 16 | 70 | 57 | warn | 26.6% |
FAQ · from the current data · as of 2026-09-23
Quick answers
argenx NV ADR在Closelook覆盖范围内的同类公司有哪些?
分组首先基于共同的Closelook指数成分,其次基于行业:BB Biotech AG (BION.SW)、Argen-X (ARGX.BR)、BeiGene, Ltd. (ONC)、Caris Life Sciences, Inc. Common Stock (CAI)、Regeneron Pharmaceuticals Inc (REGN)、UCB SA (UCB.BR)。
ARGX相对同类公司的评分如何?
argenx NV ADR的综合评分为64/100,组内排名第2位(共7家),截至2026-09-23;组内最高综合评分为BB Biotech AG(74/100)。Closelook评分为研究日记读数,不构成评级或投资建议。
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ONC BeiGene, Ltd.industry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- VKTX Viking Therapeutics Incindustry
- HALO Halozyme Therapeutics Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- RXRX Recursion Pharmaceuticals Incindustry
- SMMT Summit Therapeutics PLCindustry
- IBRX Immunitybio Incindustry
- GMAB Genmab ASindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- TGTX TG Therapeutics Incindustry
- CRSP Crispr Therapeutics AGindustry
- EXEL Exelixis Incindustry